Literature DB >> 18975020

TIMI 3 flow after primary angioplasty is an important predictor for outcome in patients with acute myocardial infarction.

Juergen Kammler1, Alexander Kypta, Robert Hofmann, Klaus Kerschner, Michael Grund, Kurt Sihorsch, Clemens Steinwender, Thomas Lambert, Wolfram Helml, Franz Leisch.   

Abstract

BACKGROUND: Growing evidence suggests that poor coronary blood flow after primary percutaneous coronary intervention (PCI) is associated with unfavorable clinical out-come. We retrospectively evaluated data from our single center "real world patients" database of patients undergoing primary PCI to determine differences in clinical and angiographic patterns in patients with or without restoring thrombolysis in myocardial infarction (TIMI) flow 3. METHODS AND
RESULTS: Between 2001 and 2006, 500 patients underwent primary PCI for STEMI. In 430 patients, post-interventional TIMI flow 3 could be established. In this group, in-hospital mortality was significant lower (6.4% Vs. 32.9%; P < 0.0001), left ventricular ejection fraction was better (51.3 Vs. 44.2%; P < 0.0001), and prehospital fibrinolytic therapy (6.3% Vs. 14.3%; P = 0.015), cardiogenic shock (10.9% Vs. 24.3%; P = 0.002) and use of intra-aortic balloon pump were all more unlikely (5.8% Vs. 11.4%; P = 0.045) compared to patients with TIMI flow < or = 2. In patients with post-interventional TIMI flow < or = 2 the left anterior descending coronary artery (LAD) was significantly more often seen as the target vessel (54.3% Vs. 44.6%; P = 0.039). A regressions analysis showed that predictors leading to such flow patterns are diabetes (P = 0.013), pre-hospital fibrinolytic therapy (P = 0.017), cardiogenic shock (P = 0.002) and a 3-vessel disease (P = 0.003). After 6 months, patients without restored normal TIMI flow had worse New York Heart Association functional class (NYHA), and had to undergo repeat coronary angiography more often.
CONCLUSION: Post-interventional TIMI flow < or = 2 is strongly associated with adverse out-come during hospitalization and after 6 months following hospitalization.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18975020      PMCID: PMC2847159          DOI: 10.1007/s00392-008-0735-9

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


Introduction

Reperfusion therapy is the cornerstone of treatment for patients with acute ST-elevation myocardial infarction (STEMI). Timely reperfusion of the infarct-related coronary artery using fibrinolysis or PCI is central to optimal STEMI treatment [1–3, 10, 15, 18]. As our treatment center has a skilled PCI laboratory with an experienced interventional cardiologist on duty 24 h a day, patients admitted to our hospital undergo primary PCI if coronary arteries are suitable, as recommend in current standard guidelines [1] within <90 min door-to-balloon time. The benefits of reperfusion therapy have been attributed to the prompt reestablishment of normal blood flow in the infarct-related artery, defined as thrombolysis in myocardial infarction (TIMI) 3 flow. We investigated the clinical outcome at index hospitalisation and after 6 months in groups of patients with or without re-established TIMI three flow, using data from our acute PCI database of a “real world” outdoor patient cohort of 500 patients treated between February 2001 and October 2006.

Methods

Patient population

Results from 500 consecutive patients treated with acute PCI in acute STEMI were retrospectively acquired. STEMI was defined as typical ischemic chest pain within the previous 12 h and ST-segment elevations of >2 mm in at least two contiguous leads. All patients underwent acute coronary angiography and, if eligible, direct or rescue angioplasty. All interventions were performed according to current standard guidelines [19-21]. As a pharmacological regimen, all patients received 500 mg Aspirin orally, 300 mg Clopidogrel and a weight adapted bolus of intravenous heparin (100 IE/kg) upon admission prior to entering the cathlab. A weight-adapted bolus (0.25 mg/kg) of abciximab (Reopro®, Lilly Corp) was also administered in all patients, with the exception of those who received prehospital fibrinolytic therapy. Administration of abciximab was established in our center as good clinical practice after data of positive impact in patients undergoing primary PCI came up [7, 9, 11]. Other medications, including betablockers, nitrates, and morphine were administered at the discretion of the physician on duty. The antegrade radiocontrast flow of the infarct-related artery was determined on the final coronary angiogram by the operator with the use of TIMI criteria. The TIMI flow grades have been defined previously [22]. In brief, grade 0 perfusion is no antegrade flow beyond the point of occlusion; grade 1 is minimal incomplete perfusion of contrast medium around the clot; grade 2 (partial perfusion) is complete but delayed perfusion of the distal coronary bed with contrast material; and grade 3 (complete perfusion) is antegrade flow to the entire distal bed at a normal rate. All patients were invited for a follow-up visit 6 months after index hospitalisation. Clinical status and 12 lead ECGs were performed routinely. An exercise test was also performed at the discretion of the physician.

Statistical analysis

A multivariate binary logistic regression analysis was performed to determine which clinical and angiographic variables would independently predict poor post-interventional coronary flow (TIMI flow ≤ 2). Variables with a P-value < 0.05 were considered statistically significant as independent predictors. Values are expressed as mean ± standard deviation or frequencies. Differences in continuous variables were analyzed using the Student’s t test. P-values < 0.05 were considered statistically significant.

Results

Baseline characteristics

The baseline characteristics are listed in Table 1. Five hundred patients underwent primary angioplasty for myocardial infarction. In all, 70 patients (14%), 21 (30%) female, did not show TIMI 3 flow after intervention. The number of patients with TIMI 0.1, and two flows were 32 patients (46%), 12 patients (17%) and 26 patients (37%) respectively. In 430 patients (86%), 111 female (25.8%), the procedure was considered complete after establishing TIMI 3 flow. In 419 out of the 430 patients with post procedural TIMI 3 flow, TIMI 3 flow was established by PCI. In 11 patients (2.6%) angioplasty was not performed for various reasons. In three patients, a pericarditis was diagnosed. Seven patients did not show angiographic stenosis ≥50%. These 10 patients (2%) were excluded from our analysis because no significant stenosis in the coronary arteries could be found. In one patient coronary morphology was not suitable for PCI and was therefore sent for acute coronary artery bypass grafting (CABG).
Table 1

Baseline characteristics of patients undergoing acute coronary angiography

TIMI flow = 3 (n = 430)TIMI flow ≤ 2 (n = 70)P-value
n (%)n (%)
Age (SD); years61 (13)64 (14)0.049
Female111 (25.8)21 (30)0.086
Onset of symptom to hospital (SD), min292.6 (527.9)341.9 (558.7)0.231
History
  Hypertension230 (53.5)32 (45.7)0.05
  Diabetes58 (13.5)19 (27.1)0.003
  Hypercholesterolemia216 (50.2)38 (54.3)0.084
  Prior PCI or myocardial infarction123 (28.6)18 (25.7%)0.103
  Prior bypass surgery13 (3.0)5 (7.1)0.064
  Current tobacco smoker135 (31.4)20 (28.5)0.101
  Prehospital thrombolytic therapy27 (6.3)10 (14.3)0.015
Clinical presentation
  Killip class > 1203 (47.2)40 (57.1)0.032
 Cardiogenic shock47 (10.9)17 (24.3)0.002

SD standard deviation, PCI percutaneous coronary intervention

Baseline characteristics of patients undergoing acute coronary angiography SD standard deviation, PCI percutaneous coronary intervention Of the 70 patients with post procedural TIMI flow ≤ 2, PCI was performed in 57 patients. 13 patients did not undergo angioplasty for various reasons. In 10 cases, PCI was not performed for technical reasons and patients were treated conservatively. One patient exhibited a closed Ramus obliquus as the target vessel, which was therefore not suitable for PCI. One patient was sent for acute coronary artery bypass grafting (CABG) as a result of a left main stem stenosis in a three vessels disease. In another patient, peripheral coronary embolism lead to ischemia and the vessel was not suitable for PCI. The interventional success rate was 82.6% in this cohort. The overall success rate was 97.6% (476 patients out of 488). Compared with the cohort with TIMI 3 flow, those with TIMI flow ≤ 2 were significantly more likely to be older, diabetic, hypertensive, and had unsuccessful prehospital fibrinolytic therapy with an indication for a “rescue PCI”. Similarly, presentation with cardiogenic shock, defined as adverse hemodynamics such as heart rate >100 beats/min and blood pressure <100 mmHg, despite adequate fluid administration, was more common in patients with TIMI flow ≤ 2. There was also a trend towards a longer period of chest pain in patients with post-interventional TIMI flow ≤ 2. However, due to a large standard deviation, a statistically significant difference was not observed.

Angiographic results and clinical outcome

Angiographic characteristics differed between the two patient groups. In this analysis, only those patients with significant coronary artery stenosis (n = 490) were included. As mentioned previously, ten patients did not undergo revascularisation (Tables 2 and 3).
Table 2

Angiographic data of patients showing significant coronary artery stenosis

TIMI flow = 3 (n = 420)TIMI flow ≤ 2 (n = 70)P-value
n (%)n (%)
Infarct-related artery
  Left anterior descending190 (45.2)38 (54.3)0.039
  Left circumflex67 (16)10 (14.3)0.137
  Right coronary152 (36.2)17 (24.3)0.016
  Saphenous vein graft6 (1.4)4 (5.7)0.033
  Left main5 (1.2)1 (1.4)0.399
  Three vessels disease76 (18.1)19 (27.1)0.027
Initial TIMI flow
  0265 (63.1)49 (70)0.059
  162 (14.8)13 (18.6)0.097
  252 (12.4)8 (11.4)0.155
  341 (9.7)0 (0)0.0013
Post-procedure TIMI flow
  00 (0)32 (45.7)
  10 (0)12 (17.1)
  20 (0)26 (37.2)
  3420 (100)0 (0)
Intra-aortic balloon pump25 (5.9)8 (11.4)0.045
Stentthrombosis34 (7.9)6 (8.6)0.179
Left ventricular ejection fraction (SD)51.3 (11.8)44.2 (13.1)0.00001

SD standard deviation, TIMI thrombolysis in myocardial infarction

Table 3

Follow up data

TIMI Flow = 3 (n = 420)TIMI Flow ≤ 2 (n = 70)P-value
n (%)n (%)
In hospital mortality27 (6.4)23 (32.9)<0.0001
6 month follow up39347
  Lost of follow up18 (4.5)3 (6.4)
  Death17 (4.2)2 (4.3)0.293
  NYHA I183 (51.1)16 (38.1)0.037
  NYHA II122 (34.1)21 (50.0)0.018
  NYHA III42 (11.7)3 (7.1)0.155
  NYHA IV11 (3.1)2 (4.8)0.258
  Cardiac catheterization133 (37.2)23 (54.7)0.012
  TVR52 (39.1)4 (17.4)0.025
  PCI of non target vessel22 (16.6)4 (17.4)0.232
  ad CABG4 (3.0)0

NYHA New York Heart Association, TVR target vessel revascularization, PCI percutaneous coronary intervention, CABG coronary artery bypass grafting, TIMI thrombolysis in myocardial infarction

Angiographic data of patients showing significant coronary artery stenosis SD standard deviation, TIMI thrombolysis in myocardial infarction Follow up data NYHA New York Heart Association, TVR target vessel revascularization, PCI percutaneous coronary intervention, CABG coronary artery bypass grafting, TIMI thrombolysis in myocardial infarction Thus, patients with TIMI flow ≤ 2 were more likely to have initial TIMI flow ≤ 1 (P = 0.015), left anterior descending and saphenous vein grafts as infarct-related artery, a left ventricular ejection fraction <50%, and were more likely to undergo rescue PCI after prehospital intravenous thrombolytic therapy and treatment with an intra-aortic balloon pump (P = 0.045). There was a significant difference observed in overall mortality during index hospitalization between patients who achieved TIMI flow ≤ 2 and TIMI flow 3 (32.9 Vs. 6.4%, P < 0.0001) after their primary PCI. Follow-up mortality after 6 months was not statistically different between the two groups. However, presentation of New York heart association classification (NYHA-Class) at the 6-month follow-up visit was significantly different. Patients with TIMI flow ≤ 2 were more likely to present in NYHA class ≥1 and to undergo repeated coronary angiography. However, target vessel revascularisation in these catheterizations was performed more often in the patients with post-interventional TIMI flow 3 (P = 0.025).

Predictors of TIMI flow ≤ 2

Resorting to stepwise logistic regression, four independent predictors of TIMI flow ≤ 2 were identified: prehospital thrombolytic therapy, cardiogenic shock, three vessel disease, and diabetes mellitus. The most powerful predictors were cardiogenic shock and three vessel disease. Prehospital thrombolytic therapy and diabetes mellitus were also associated with a higher probability of a TIMI flow ≤ 2. The overall predictability of the regression model was 85.8% (Table 4).
Table 4

Logistic regression analysis for independent predictors of postinterventional TIMI flow ≤ 2

VariableBeta coefficientStandard errorP-valueOdds ratio95% confidence intervall
Cardiogenic shock0.9930.3260.0022.7001.425–5.116
Three vessel disease0.8770.2940.0032.4041.351–4.277
Prehospital thrombolytic therapy0.9760.4080.0172.6531.191–5.906
Diabetes mellitus0.7810.3160.0132.1851.176–4.060
Constant−2.4820.201<0.0010.084

TIMI thrombolysis in myocardial infarction

Logistic regression analysis for independent predictors of postinterventional TIMI flow ≤ 2 TIMI thrombolysis in myocardial infarction

Discussion

Successful reperfusion therapy, achieved through mechanical or pharmacological intervention, is the goal in the treatment of patients with STEMI [3, 10, 18]. The objective of all interventions is restoration of normal TIMI 3 flow within the epicardial coronary vessels. Time to reperfusion is an important factor in this topic, as described previously [5, 23]. This could give an account for worse outcome in patients after unsuccessful prehospital fibrinolytic therapy with an indication for a “rescue PCI”. Rescue patients evolve larger infarctions, likely explained by delay to reperfusion [4]. On the other hand we did not administer abciximab in these patients which might additionally have an impact on TIMI flow and clinical outcome. For this topic further investigation is needed in order to establish therapeutical regimen with GPIIb/IIIa antagonists on top of a failed thombolytic therapy. The study populations in previously published data discussing the influence of TIMI flow on angiographic and clinical results are different from the study population evaluated here. Previous studies excluded patients after prehospital fibrinolysis, and patients with cardiogenic shock, renal insufficiancy, or those with child-bearing potential (unless the result of a recent pregnancy test was negative) [12], or compared different therapeutical regimens [6]. We present data of a single center “real world cohort” of 500 patients admitted to our hospital with STEMI. As PCI was attempted in many patients that would have been excluded in former randomized trials, restoration was not feasible in all patients despite high levels of technical experience amongst the operators, as an overall success rate of 97.6% indicates. Putative mechanisms for suboptimal post-interventional epicardial coronary flow, known as “no reflow phenomenon”, may be a multi-factor condition reflecting damage to microvascular integrity incurred both during ischemia and at the time of reperfusion. Possible related factors are microvascular damage or edema, neutrophil plugging of the microvessels, micorovascular spasm, distal embolization of thrombus, and debris, or poor PCI result with a significant residual stenosis, dissection, or mural thrombosis [13, 14, 16, 17]. The post-interventional TIMI flow is an important prognostic value for in-hospital mortality and clinical outcome 6 months post-hospitalization [8]. This analysis of a “real world patient cohort” demonstrates that the success rate of primary PCI is lower in older patients than in younger patients, and this finding is associated with a higher mortality with primary PCI during STEMI in elderly patients. In addition, patients with STEMI showing the left anterior descending coronary artery or saphenous vein grafts as the culprit vessel are more likely to have poor final coronary blood flow. Overall, age, clinical presentation, and infarct localization appear to be important factors impacting the outcome in patients with STEMI undergoing primary PCI. Predictors for poor post-interventional flow in the coronary arteries are three vessels disease, cardiogenic shock, diabetes mellitus, and inefficient prehospital thrombolytic therapy. A finding that has not been previously described is that patients undergoing rescue PCI due to inefficient intravenous fibrinolytic therapy have a post-interventional TIMI flow ≤ 2 significantly more often. These findings warrant further evaluation. It is most plausible that the mechanisms described above result in impaired flow in the coronary arteries if pharmacological reperfusion is not successful. Patients with TIMI flow ≤ 2 exhibited worse NYHA class at the 6 month follow-up visit, requiring coronary angiography more frequently at this timepoint in order to obtain invasive control. However, the rate of target vessel revascularisation following the decision to obtain invasive control at the 6 month follow-up visit was significantly lower in these patients. This may, on the one hand, be the result of the higher incidence of three vessel disease in these patients, without the need for another PCI (total chronic occlusion; no angiographic significant stenosis (<60%)). On the other hand, as is the case in this patient group, age is associated with higher levels of sclerosis in the small lumen diameter vessels, without the possibility of mechanical intervention resulting in stable angina upon long term follow up.

Conclusion

The inability to achieve successful coronary reperfusion is associated with a higher mortality in patients with acute myocardial infarction undergoing primary angioplasty. Prehospital fibrinolytic therapy, age, and infarct localisation increase the risk of poor final coronary blood flow. Post- interventional TIMI flow ≤ 2 is associated with a worse NYHA class at a 6 month follow-up visit, requiring a significantly higher number of repeated coronary angiograms to assess invasive coronary status.
  23 in total

1.  ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention).

Authors:  Sidney C Smith; Ted E Feldman; John W Hirshfeld; Alice K Jacobs; Morton J Kern; Spencer B King; Douglass A Morrison; William W O'Neill; Hartzell V Schaff; Patrick L Whitlow; David O Williams; Elliott M Antman; Cynthia D Adams; Jeffrey L Anderson; David P Faxon; Valentin Fuster; Jonathan L Halperin; Loren F Hiratzka; Sharon Ann Hunt; Rick Nishimura; Joseph P Ornato; Richard L Page; Barbara Riegel
Journal:  Circulation       Date:  2006-01-03       Impact factor: 29.690

2.  Angiographic morphologic features of infarct-related arteries and timely reperfusion in acute myocardial infarction: predictors of slow-flow and no-reflow phenomenon.

Authors:  Hon-Kan Yip; Mien-Cheng Chen; Hsueh-Wen Chang; Chi-Ling Hang; Yuan-Kai Hsieh; Chih-Yuan Fang; Chiung-Jen Wu
Journal:  Chest       Date:  2002-10       Impact factor: 9.410

3.  Incidence and treatment of 'no-reflow' after percutaneous coronary intervention.

Authors:  R N Piana; G Y Paik; M Moscucci; D J Cohen; C M Gibson; A D Kugelmass; J P Carrozza; R E Kuntz; D S Baim
Journal:  Circulation       Date:  1994-06       Impact factor: 29.690

4.  ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction).

Authors:  Elliott M. Antman; Daniel T. Anbe; Paul Wayne Armstrong; Eric R. Bates; Lee A. Green; Mary Hand; Judith S. Hochman; Harlan M. Krumholz; Frederick G. Kushner; Gervasio A. Lamas; Charles J. Mullany; Joseph P. Ornato; David L. Pearle; Michael A. Sloan; Sidney C. Smith; Joseph S. Alpert; Jeffrey L. Anderson; David P. Faxon; Valentin Fuster; Raymond J. Gibbons; Gabriel Gregoratos; Jonathan L. Halperin; Loren F. Hiratzka; Sharon Ann Hunt; Alice K. Jacobs; Joseph P. Ornato
Journal:  J Am Coll Cardiol       Date:  2004-08-04       Impact factor: 24.094

Review 5.  Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials.

Authors:  David E Kandzari; Vic Hasselblad; James E Tcheng; Gregg W Stone; Robert M Califf; Adnan Kastrati; Franz-Josef Neumann; Sorin J Brener; Gilles Montalescot; David F Kong; Robert A Harrington
Journal:  Am Heart J       Date:  2004-03       Impact factor: 4.749

6.  The effects of facilitated primary PCI by guide wire on procedural and clinical outcomes in acute ST-segment elevation myocardial infarction.

Authors:  Volkhard Kurowski; Evangelos Giannitsis; Dirk P Killermann; Uwe K H Wiegand; Ralph Toelg; Hendrik Bonnemeier; Franz Hartmann; Hugo A Katus; Gert Richardt
Journal:  Clin Res Cardiol       Date:  2007-06-04       Impact factor: 5.460

7.  Risk predictors for adverse outcomes after percutaneous coronary interventions and their related costs.

Authors:  Michele Pohlen; Holger Bunzemeier; Wibke Husemann; Norbert Roeder; Günter Breithardt; Holger Reinecke
Journal:  Clin Res Cardiol       Date:  2008-03-03       Impact factor: 5.460

8.  Troponin level and efficacy of abciximab in patients with acute coronary syndromes undergoing early intervention after clopidogrel pretreatment.

Authors:  Raisuke Iijima; Gjin Ndrepepa; Julinda Mehilli; Franz-Josef Neumann; Stefanie Schulz; Jurriën ten Berg; Olga Bruskina; Franz Dotzer; Josef Dirschinger; Peter B Berger; Albert Schömig; Adnan Kastrati
Journal:  Clin Res Cardiol       Date:  2007-11-28       Impact factor: 5.460

9.  Effects of the early administration of heparin in patients with ST-elevation myocardial infarction treated by primary angioplasty.

Authors:  Woo-Young Chung; Mi-Jung Han; Young-Seok Cho; Kwang-Il Kim; Hyuk-Jai Chang; Tae-Jin Youn; In-Ho Chae; Dong-Ju Choi; Cheol-Ho Kim; Byung-Hee Oh; Young-Bae Park; Yun-Shik Choi
Journal:  Circ J       Date:  2007-06       Impact factor: 2.993

10.  Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology.

Authors:  Sigmund Silber; Per Albertsson; Francisco F Avilés; Paolo G Camici; Antonio Colombo; Christian Hamm; Erik Jørgensen; Jean Marco; Jan-Erik Nordrehaug; Witold Ruzyllo; Philip Urban; Gregg W Stone; William Wijns
Journal:  Eur Heart J       Date:  2005-03-15       Impact factor: 29.983

View more
  18 in total

1.  One-year clinical outcomes with abciximab in acute myocardial infarction: results of the BRAVE-3 randomized trial.

Authors:  Stefanie Schulz; K Anette Birkmeier; Gjin Ndrepepa; Werner Moshage; Franz Dotzer; Kurt Huber; Josef Dirschinger; Melchior Seyfarth; Albert Schömig; Adnan Kastrati; Julinda Mehilli
Journal:  Clin Res Cardiol       Date:  2010-06-27       Impact factor: 5.460

2.  Impact of minimising door-to-balloon times in ST-elevation myocardial infarction to less than 30 min on outcome: an analysis over an 8-year period in a tertiary care centre.

Authors:  Ulrike M Müller; Ingo Eitel; Kristina Eckrich; Sandra Erbs; Axel Linke; Sven Möbius-Winkler; Meinhard Mende; Gerhard C Schuler; Holger Thiele
Journal:  Clin Res Cardiol       Date:  2010-10-24       Impact factor: 5.460

3.  Percutaneous coronary intervention of severely/moderately calcified coronary lesions using single-burr rotational atherectomy: A retrospective study.

Authors:  Shuvanan Ray; Siddhartha Bandyopadhyay; Prithwiraj Bhattacharjee; Priyam Mukherjee; Suman Karmakar; Sabyasachi Mitra; Anirban Dalui; Ashok Dhar
Journal:  Anatol J Cardiol       Date:  2021-06       Impact factor: 1.596

4.  Patients with microvascular obstruction after primary percutaneous coronary intervention show a gp91phox (NOX2) mediated persistent oxidative stress after reperfusion.

Authors:  Giampaolo Niccoli; Andrea Celestini; Camilla Calvieri; Nicola Cosentino; Elena Falcioni; Roberto Carnevale; Cristina Nocella; Francesco Fracassi; Marco Roberto; Roberta P Antonazzo; Pasquale Pignatelli; Filippo Crea; Francesco Violi
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2013-09-05

5.  The impact of right ventricular function assessed by 2-dimensional speckle tracking echocardiography on early mortality in patients with inferior myocardial infarction.

Authors:  Batur G Kanar; Mustafa K Tigen; Murat Sunbul; Altug Cincin; Halil Atas; Alper Kepez; Beste Ozben
Journal:  Clin Cardiol       Date:  2018-03-25       Impact factor: 2.882

6.  Direct admission versus transfer of AMI patients for primary PCI.

Authors:  Christoph Liebetrau; Sebastian Szardien; Johannes Rixe; Mariella Woelken; Andreas Rolf; Timm Bauer; Holger Nef; Helge Möllmann; Christian Hamm; Michael Weber
Journal:  Clin Res Cardiol       Date:  2010-09-21       Impact factor: 5.460

7.  Age-related differences in antithrombotic therapy, success rate and in-hospital mortality in patients undergoing percutaneous coronary intervention: results of the quality control registry of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte (ALKK).

Authors:  Arne Kristian Schwarz; Ralf Zahn; Matthias Hochadel; Sebastian Kerber; Karl E Hauptmann; Hans-Georg Glunz; Harald Mudra; Harald Darius; Uwe Zeymer
Journal:  Clin Res Cardiol       Date:  2011-04-21       Impact factor: 5.460

8.  Prognostic value of minimal blood flow restoration in patients with acute myocardial infarction after reperfusion therapy.

Authors:  Gjin Ndrepepa; Dritan Keta; Stefanie Schulz; Robert A Byrne; Julinda Mehilli; Jürgen Pache; Melchior Seyfarth; Albert Schömig; Adnan Kastrati
Journal:  Clin Res Cardiol       Date:  2009-09-10       Impact factor: 5.460

9.  Predictors of delayed and no-reflow as recognized with Thrombolysis in Myocardial Infarction [TIMI] flow grade following Primary Percutaneous Coronary Angioplasty.

Authors:  M Bahrehmand; E Sadeghi; A Shafiee; Y Nozari
Journal:  J Med Life       Date:  2015

10.  Risk assessment in patients with an acute ST-elevation myocardial infarction.

Authors:  Nadeem Ahmed; Jaclyn Carberry; Vannesa Teng; David Carrick; Colin Berry
Journal:  J Comp Eff Res       Date:  2016-09-01       Impact factor: 1.744

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.